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In Brazil the knowledge about methicillin-resistant Staphylococcus aureus infection in cys-
tic  ﬁbrosis patients is scarce. This study aimed to determine the incidence of respiratory
tract colonization and the identiﬁcation rates after a standardized treatment. A retrospec-
tive cohort was performed highlighting the history of respiratory colonizations between
January 2008 and June 2015. Patients under the age of 21 years with cystic ﬁbrosis conﬁrmed
by  sweat test or genetic study receiving care at the outpatient clinics of a Teaching Hospi-
tal  were included. The treatment consisted of trimethoprim/sulfamethoxazole, rifampicin,
nasal mupirocin and chlorhexidine 2%. The mean follow-up period was of 22.2 months and
those  with ≥3 negative cultures were considered free of methicillin-resistant Staphylococ-
cus aureus. Forty-two patients were included. Methicillin-resistant Staphylococcus aureus was
identiﬁed in six patients. Most patients had methicillin-sensitive S. aureus isolation prior to
methicillin-resistant Staphylococcus aureus.  Five children used the standardized treatment,
none presented side effects. Only one child had a new isolation of methicillin-resistant
Staphylococcus aureus during follow-up (after 20 months). The incidence of methicillin-
resistant Staphylococcus aureus infection was high and occurred in young patients. The
therapeutic regimen was effective, safe and being a good option to treat methicillin-resistantStaphylococcus aureus infection.
© 2016 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda. This is an
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Cystic ﬁbrosis (CF) clinical manifestations are highly vari-
able and respiratory tract infections (RTI) are responsible
for high morbidity and mortality rates. Identifying and bet-
ter understanding the respiratory tract pathogens in those
patients is therefore of utmost importance.1
Staphylococcus aureus is one of the ﬁrst and most frequent
pathogens to be isolated from the respiratory tract in CF
patients.2 This microorganism is a Gram-positive coccus with
a typically aerobic metabolism that can also perform as a fac-
ultative anaerobic and is capable of producing bioﬁlm.2
In the last decades the increased life expectancy of CF
patients can be related to advances in the treatment of
chronic pulmonary infections and also to patient follow-up
by multidisciplinary healthcare teams.1 The emergence of
multi-resistant microorganisms is mainly a result of multiple
antibiotic cycles in the treatment of RTI1 and to long-lasting
hospitalizations.3
The isolation of methicillin-resistant S. aureus (MRSA) was
ﬁrst observed in 1961.2 Resistance is acquired through the
mecA gene located on the Staphylococcal cassette chromosome
mec  complex (SCCmec).4 Based on its structural composition,
11 different types (I-XI) and various subtypes of SCCmec have
been recognized in MRSA so far.3,4 Initially, MRSA infections
were only described in the hospital environment. However, in
the 90s MRSA began to be observed also in the community.2
The prevalence of MRSA colonization in CF patients has
been increasing in the USA for the last 15 years,2,3,5,6 being
variable in diverse geographic regions, ranging from 2.7% in
the United Kingdom to 30% in the United States.2,3,7,8 There
are doubts regarding the natural course and pathogenic impor-
tance of the infection caused by this microorganism, although
it is possibly associated with a more  rapid decrease in lung
function and higher morbidity and mortality.9,10 The role of
MRSA eradication treatment in order to prevent chronic infec-
tion is also unclear3 and there is no consensus about the ideal
therapeutic regimen and various regimens are currently in
use.2,3,11
In Brazil the knowledge about MRSA colonization in CF
patients is scarce. A study carried out in 2006 in a reference
center in Bahia identiﬁed that the frequency of MRSA colo-
nization was 6%12 and Simon et al.13 detected a frequency of
18.8% in CF patients at a center in Porto Alegre. Data from the
Brazilian Cystic Fibrosis Registry (BCFR) show a frequency of
MRSA isolation varying from 7.8% to 9.3% between 2009 and
2013.14
This study aimed to determine the incidence of respira-
tory tract colonization by MRSA and to assess the persistence
rates of the microorganism after administering a standardized
treatment in CF pediatric patients followed at the Multidis-
ciplinary Cystic Fibrosis Clinic at the Prof. Edgard Santos
Teaching Hospital, Salvador, Brazil. This clinic provides treat-
ment for children and adolescents (0–20 years old) mostly from
low income families and with high level of miscegenation.
A retrospective cohort study was conducted searching for
history of respiratory colonization among CF children and ado-
lescents under 21 years of age followed at the Multidisciplinary
Cystic Fibrosis Clinic at the Prof. Edgard Santos Teaching Hos-Please cite this article in press as: Bittencourt PH, et al. Incidence and tr
patients: a cohort study. Braz J Infect Dis. 2016. http://dx.doi.org/10.1016/j.
pital in the period of January 2008 and June 2015. The patients
included in the study had a CF diagnosis conﬁrmed by elevated
sweat chloride tests on two different occasions. 6;x x x(x x):xxx–xxx
Data used in this study were retrieved from patients’ med-
ical charts and the following variables were collected: sex;
ethnicity; current age, age at the diagnosis and age at the ﬁrst
isolation of methicillin-sensitive S. aureus (MSSA) and MRSA;
number of MRSA-positive samples for each patient; previous
MSSA identiﬁcation; Pseudomonas aeruginosa prior to and/or
after the MRSA isolation; genotype; use of standardized treat-
ment.
Patients’ follow-up visits at the Multidisciplinary Cystic
Fibrosis Clinic usually were scheduled every three months
and collection of respiratory secretions by the physiothera-
pist is done at every visit. Samples were preferably obtained
via expectorated sputum or by oropharyngeal swab when the
former way was not possible and the material was immedi-
ately sent to the microbiology lab for culture. Upon arrival,
samples were processed in blood agar, chocolate agar, Mac-
Conkey agar and selective medium for Burkholderia cepacia
complex. Plates with creamy white hemolytic colonies, sug-
gestive of S. aureus,  were Gram stained and the phenotypic
coagulase test was performed using Staphytest – PROBAC®.
Gram-positive coagulase-positive samples were then submit-
ted to an antimicrobial susceptibility test for the detection of
MRSA using a cefoxitin 30 g disk in Mueller–Hinton medium.
Cefoxitin-resistant isolates were considered MRSA according
to the Clinical and Laboratory Standards Institute (CLSI).15 The
standard American Type Culture Collection (ATCC) S. aureus
was used as a control for the quality of the medium and disks
used.
All patients with MRSA isolation between January 2013 and
August 2014 received a standardized treatment consisting of
an oral association of trimethoprim/sulfamethoxazole plus
rifampicin for 14 days, besides nasal mupirocin and corporal
hygiene of the patient and family members with chlorhexi-
dine 2%, both for one week. After treatment, patients were
followed-up until June 2015 and those with at least three neg-
ative cultures during this period were considered free of MRSA.
Descriptive analysis was performed using Epidata soft-
ware and the following descriptive statistics were calculated:
median, mean, standard deviation, amplitude, simple and
relative frequencies. The study was approved by the Inter-
nal Review Board of Prof. Edgard Santos Teaching Hospital
under approval number 121/2011. Informed consent state-
ments were signed by one of the parents, for patients under
18 years old, and, for the others, by the own patient.
Overall, 42 patients were included in the study with a mean
age of 9.9 years (SD = 5.4) ranging from 1 to 20.8 years. From
those, 22 (52.4%) patients were male. Eight patients followed
at the cystic ﬁbrosis Clinic were excluded: three had suppu-
rative lung disease and chronic respiratory tract colonization
by mucoid P. aeruginosa but normal sweat tests, and three had
borderline sweat tests. All patients were non-white. The allelic
frequency for the Phe508del mutation was 25%. During the
study period, MRSA was identiﬁed in six patients (14.3%) and
their clinical data are displayed on Table 1. Two children had
more  than one isolation of this microorganism (four and eight,
respectively). The sensitivity proﬁles of this microorganismeatment of methicillin-resistant S. aureus infection in cystic ﬁbrosis
bjid.2016.09.003
vancomycin, among other tested antibiotics.
In the six patients in whom MRSA was isolated, the median
age at CF diagnosis was 8 months, varying from three to
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Table 1 – Clinical data from the six patients with MRSA isolation from 2011 to 2014.
Name Age
diagnosis
AFI MRSA Genotype NI MRSAa AFI MSSA MSSA before
MRSA
PA  before
MRSA
PA after
MRSA
Patient 1 10 9 Phe508del/N 1 – No Yes No
Patient 2 73  124 N/N 1 77 Yes Yes Yes
Patient 3b 3 3 Phe508del/Phe508del 8 0.7 Yes Yes Yes
Patient 4c 6 14 Phe508del/3120 + 1G-A 1 5 Yes Yes Yes
Patient 5 57 103 Phe508del/N 4 101 Yes No Yes
Patient 6c 3 8 Phe508del/3120 + 1G-A 1 15 Yes No Yes
Age at the diagnosis (in months).
AFI, age at the ﬁrst isolation (in months); NI, number of isolations; N, normal allele for the six tested mutations; MSSA, methicillin-sensitive S.
aureus; MRSA, methicillin-resistant S. aureus; PA, Pseudomonas aeruginosa.
a All isolated strains were sensitive to trimethoprim/sulfamethoxazole and vancomycin.
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pb MRSA isolated in a blood culture sample.
c Patients are siblings but they were both included in the study for p
3 months. The median age at the ﬁrst MRSA identiﬁcation
as 11.5 months, ranging from three to 124 months, and the
edian age at the ﬁrst MSSA isolation was 15 months, which
aried from 0.7 to 101 months. Most patients (83.3%) presented
t least one MSSA isolation prior to MRSA detection, and one P.
eruginosa identiﬁcation prior to (66.7%) and post (83.3%) MRSA
etection.
Five children with MRSA isolated after 2013 were treated
ith the above described regimen and none of them pre-
ented side effects during the period of the study. Respiratory
ecretions were collected in at least three occasions during
ix months after treatment. All children were young and/or
on-suppurative so all microbiological samples were collected
sing oropharyngeal swab. Only the child with eight MRSA
solations (including one in blood culture) had a new isola-
ion during the follow-up period. Table 2 presents data of the
espiratory specimens studied during follow-up.
The incidence of MRSA colonization in this study (14.3%)
as higher than that reported in a previous study conducted
n Salvador12 and in the BCFR between 2009 and 2013,14 but
ower than the rate found by Simon et al.13 It is important
o highlight that our study sample was consisted mostly of
ounger children and there were limitations in the collection
f the respiratory secretions; thus, the frequency of isolation
f this microorganism could have been underestimated.
The median age at the ﬁrst MRSA colonization in the
resent study was 11.5 months (3–124) evidencing a very early
dentiﬁcation of this microorganism since 50% of the children
ad their ﬁrst isolation before the ﬁrst year of life, which is
n accordance with the study conducted by Salsgiver et al.6
hat demonstrated higher incidence of MRSA detection in this
ge group. It is also possible that the socioeconomic charac-
eristics of our population contribute to a higher occurrence
f MRSA, as suggested by David et al.16
P. aeruginosa was identiﬁed in 4 out of 6 patients (66.7%)
nd 5 out of 6 patients (83.3%) prior to and after MRSA isola-
ion, respectively. The use of multiple antibiotics could have
redisposed isolation of new pathogens.17
It is important to highlight that the allelic frequency for
he Phe508del was of 25% in the studied population, whichPlease cite this article in press as: Bittencourt PH, et al. Incidence and tr
patients: a cohort study. Braz J Infect Dis. 2016. http://dx.doi.org/10.1016/j.
iffers from much higher ﬁgures observed in studies with
aucasian populations.18,19 However, most MRSA colonized
atients (83.3%) presented this mutation, being heterozygousting isolations in different occasions.
in four of those, and homozygous in one patient, with allelic
frequency of 50%, suggesting an association with a genotype
related to a more  severe disease, which is a risk factor for
MRSA infection. Similarly to that, Al-Zubeidi et al.20 observed
that 93% of the patients with positive culture for MRSA pre-
sented this mutation and most of them were homozygous
(70%).
During the follow-up period only one child had a new MRSA
isolation after being treated with the standardized regimen. It
is important to emphasize that there was a 20-month delay for
a positive culture in this patient. There is no consensus about
the ideal treatment for MRSA infection. Various regimens have
been proposed, with different means of administration and
duration. However, there are few controlled studies with the
evaluation of possible side effects.2,11 The treatment regimen
used in this study demonstrated to be effective, besides hav-
ing the advantages of being oral, with comfortable dosage
and the possibility of being used in early ages for a brief
period of time. Nonetheless, randomized studies should be
conducted, with larger sample sizes and careful side-effects
monitoring.
Among the limitations of this study are the small sam-
ple size, consisting only of children and adolescents, selected
at only one reference center, and the retrospective data col-
lection. Besides that, included patients were mostly young
and non-suppurative children, which limited the collection
of expectorated sputum for the isolation of microorganisms,
a technique that has higher sensitivity when compared to
oropharyngeal swab. More sensitive techniques such as bron-
choalveolar lavage were not used, nor the determination of
MRSA genotype. Therefore, it was impossible to identify the
strains and the most common types and subtypes found,
which could have helped to determine if MRSA was hospital
or community acquired. Notwithstanding, the susceptibility
proﬁles identiﬁed suggest that microorganisms found were
community acquired. The follow-up time and age group stud-
ied did not allow us to rule out any late outcomes. On the other
hand, the results allowed us to know the incidence of MRSA in
the group of children with CF in this multidisciplinary center
and suggested that the treatment used was effective in reduc-eatment of methicillin-resistant S. aureus infection in cystic ﬁbrosis
bjid.2016.09.003
ing the rates of MRSA identiﬁcation while also making possible
the adoption of measures to control cross-infection between
patients.
ARTICLE IN PRESSBJID-643; No. of Pages 5
4  b r a z j i n f e c t d i s . 2 0 1 6;x x x(x x):xxx–xxx
Table 2 – Respiratory specimens studied during follow-up of the ﬁve children that used the standardized treatment.
Name Follow-up
period (months)
Number of
cultures
MRSA isolation
after treatment
Number of months until
new MRSA isolation
Microorganisms isolated
after MRSA treatment
Patient 1 24 10 No – None
Patient 2 9 6 No – PA
Patient 3 20 10 Yes 20 PA, MSSA, MRSA, Haemophillus spp.
Patient 4 30 10 No – PA, MSSA, Haemophillus spp.
Patient 5 28 13 No – MSSA, Haemophillus spp.
illin-
r
1
1
1
1
1
1
1PA, P. aeruginosa;  MSSA, methicillin-sensitive S. aureus; MRSA, methic
There was a high incidence of MRSA in the studied popula-
tion. The treatment used was effective and safe and should be
considered as a therapeutic option for this patient population.
Considering these results and the inﬂuence of this pathogen
in the outcomes of pulmonary disease in CF we  highlight the
importance of performing controlled studies with extended
number of patients so that effective MRSA eradication strate-
gies can be developed.
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